Targeting drivers of melanoma with synthetic small molecules and phytochemicals

Cancer Letters

Volumn 359, Issue 1, 2015, Pages 20-35

  Strickland, Leah Ray ^a   Pal, Harish Chandra ^a   Elmets, Craig A ^a   Afaq, Farrukh ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Melanoma; Phytochemicals; Signaling pathways; Targeted therapy

Indexed keywords

B RAF KINASE; CARBOPLATIN; CISPLATIN; CURCUMIN; DABRAFENIB; DACARBAZINE; DACTOLISIB; EPIGALLOCATECHIN GALLATE; FISETIN; IMATINIB; MAMMALIAN TARGET OF RAPAMYCIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NILOTINIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PIMASERTIB; PLANT MEDICINAL PRODUCT; PROTEIN KINASE B; RAS PROTEIN; RESVERATROL; SELUMETINIB; SILYMARIN; SORAFENIB; STEM CELL FACTOR; TEMOZOLOMIDE; TIPIFARNIB; TRAMETINIB; UNINDEXED DRUG; VEMURAFENIB; ANGIOGENESIS INHIBITOR; ANTIBODY; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

CANCER COMBINATION CHEMOTHERAPY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; ENZYME PHOSPHORYLATION; HUMAN; MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN; PROTEIN FUNCTION; SHORT SURVEY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; ANIMAL; DRUG DESIGN; DRUG EFFECTS; ENZYMOLOGY; GENETICS; PATHOLOGY; SKIN NEOPLASMS;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG DESIGN; HUMANS; MELANOMA; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 84922246385     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2015.01.016     Document Type: Review

References (207)

1. Jerant A.F., Johnson J.T., Sheridan C.D., Caffrey T.J. Early detection and treatment of skin cancer. Am. Fam. Physician 2000, 62:357-368. 375-376, 381-382.
2. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J. Clin 2014, 64:9-29.
3. Garibyan L., Fisher D.E. How sunlight causes melanoma. Curr. Oncol. Rep 2010, 12:319-326.
4. Balch C.M., et al. Final Version of 2009 AJCC melanoma staging and classification. J. Clin. Oncol 2009, 27:6199-6206.
5. Flaherty K.T. Chemotherapy and targeted therapy combinations in advanced melanoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res 2006, 12:2366s-2370s.
6. Robert C., et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014, 384:1109-1117.
7. Hodi F.S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med 2010, 363:711-723.
8. Topalian S.L., et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol 2014, 32:1020-1030.
9. Nikolaou V.A., Stratigos A.J., Flaherty K.T., Tsao H. Melanoma: new insights and new therapies. J. Invest. Dermatol 2012, 132:854-863.
10. Sacks D.B. The role of scaffold proteins in MEK/ERK signalling. Biochem. Soc. Trans 2006, 34:833-836.
11. Liang H., Liu T., Chen F., Liu Z., Liu S. A full-length 3D structure for MAPK/ERK kinase 2 (MEK2). Sci. China Life Sci 2011, 54:336-341.
12. Akinleye A., Furqan M., Mukhi N., Ravella P., Liu D. MEK and the inhibitors: from bench to bedside. J. Hematol. Oncol 2013, 6:27.
13. Hocker T.L., Singh M.K., Tsao H. Melanoma genetics and therapeutic approaches in the 21st century: moving from the benchside to the bedside. J. Invest. Dermatol 2008, 128:2575-2595.
14. Seger R., Krebs E.G. The MAPK signaling cascade. FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol 1995, 9:726-735.
15. Steelman L.S., et al. JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis. Leukemia 2004, 18:189-218.
16. Pylayeva-Gupta Y., Grabocka E., Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 2011, 11:761-774.
17. Van 't Veer L.J., et al. N-ras mutations in human cutaneous melanoma from sun-exposed body sites. Mol. Cell. Biol 1989, 9:3114-3116.
18. Eskandarpour M., et al. Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int. J. Cancer J. Int. Cancer 2005, 115:65-73.
19. Brose M.S., et al. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res 2002, 62:6997-7000.
20. Dahl C., Guldberg P. The genome and epigenome of malignant melanoma. APMIS Acta Pathol. Microbiol. Immunol. Scand 2007, 115:1161-1176.
21. Posch C., Ortiz-Urda S. NRAS mutant melanoma - undrugable?. Oncotarget 2013, 4:494-495.
22. Cox A.D., Der C.J. Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?. Biochim. Biophys. Acta 1997, 1333:F51-F71.
23. Wlodarczyk N., et al. In vitro and in vivo evaluation of two rational-designed nonpeptidic farnesyltransferase inhibitors on HT29 human colon cancer cell lines. Oncol. Res 2005, 16:107-118.
24. Gajewski T.F., et al. Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104). J. Transl. Med 2012, 10:246.
25. Sebti S.M., Der C.J. Opinion: searching for the elusive targets of farnesyltransferase inhibitors. Nat. Rev. Cancer 2003, 3:945-951.
26. Whyte D.B., et al. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem 1997, 272:14459-14464.
27. Smalley K.S.M., Eisen T.G. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int. J. Cancer J. Int. Cancer 2003, 105:165-175.
28. Morgillo F., Lee H.-Y. Lonafarnib in cancer therapy. Expert Opin. Investig. Drugs 2006, 15:709-719.
29. Niessner H., et al. The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells. J. Invest. Dermatol 2011, 131:468-479.
30. Hong D.S., et al. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res 2009, 15:7061-7068.
31. Hatzivassiliou G., et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 2010, 464:431-435.
32. Heidorn S.J., et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 2010, 140:209-221.
33. Thumar J., Shahbazian D., Aziz S.A., Jilaveanu L.B., Kluger H.M. MEK targeting in N-RAS mutated metastatic melanoma. Mol. Cancer 2014, 13:45.
34. Ascierto P.A., et al. MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 2013, 14:249-256.
35. Kaplan F.M., Shao Y., Mayberry M.M., Aplin A.E. Hyperactivation of MEK-ERK1/2 signaling and resistance to apoptosis induced by the oncogenic B-RAF inhibitor, PLX4720, in mutant N-RAS melanoma cells. Oncogene 2011, 30:366-371.
36. Halaban R., et al. PLX4032, a selective BRAF(V600E) kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAF melanoma cells. Pigment. Cell Melanoma Res 2010, 23:190-200.
37. Roskoski R. RAF protein-serine/threonine kinases: structure and regulation. Biochem. Biophys. Res. Commun 2010, 399:313-317.
38. Davies H., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954.
39. Karasarides M., et al. B-RAF is a therapeutic target in melanoma. Oncogene 2004, 23:6292-6298.
40. Hoeflich K.P., et al. Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. Cancer Res 2006, 66:999-1006.
41. Pollock P.M., et al. High frequency of BRAF mutations in nevi. Nat. Genet 2003, 33:19-20.
42. Sharpless N.E., DePinho R.A. Cancer: crime and punishment. Nature 2005, 436:636-637.
43. Wilhelm S.M., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004, 64:7099-7109.
44. Eisen T., et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer 2006, 95:581-586.
45. Hauschild A., et al. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol 2009, 27:2823-2830.
46. Flaherty K.T., et al. Phase III trial of carboplatin and paclitaxel with or without sorafenib in metastatic melanoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol 2013, 31:373-379.
47. Whittaker S., et al. Gatekeeper mutations mediate resistance to BRAF-targeted therapies. Sci. Transl. Med 2010, 2:35ra41.
48. Tsai J., et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:3041-3046.
49. Joseph E.W., et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:14903-14908.
50. Flaherty K.T., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med 2010, 363:809-819.
51. Sosman J.A., et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N. Engl. J. Med 2012, 366:707-714.
52. McArthur G.A., et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014, 15:323-332.
53. Falchook G.S., et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial. Lancet 2012, 379:1893-1901.
54. Ascierto P.A., et al. Phase II trial (BREAK-2) of the BRAF inhibitor dabrafenib (GSK2118436) in patients with metastatic melanoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol 2013, 31:3205-3211.
55. Hauschild A., et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet 2012, 380:358-365.
56. Salama A.K.S., Flaherty K.T. BRAF in melanoma: current strategies and future directions. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res 2013, 19:4326-4334.
57. Montagut C., et al. Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 2008, 68:4853-4861.
58. Corcoran R.B., et al. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signal 2010, 3:ra84.
59. Nazarian R., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 2010, 468:973-977.
60. Wagle N., et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol 2011, 29:3085-3096.
61. Villanueva J., et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 2010, 18:683-695.
62. Poulikakos P.I., et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 2011, 480:387-390.
63. Poulikakos P.I., Zhang C., Bollag G., Shokat K.M., Rosen N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 2010, 464:427-430.
64. Su F., et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med 2012, 366:207-215.
65. Le K., Blomain E.S., Rodeck U., Aplin A.E. Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib-resistant melanoma cells. Pigment. Cell Melanoma Res 2013, 26:509-517.
66. Klein O., et al. BRAF inhibitor activity in V600R metastatic melanoma. Eur. J. Cancer Oxf. Engl. 1990 2013, 49:1073-1079.
67. Shi H., et al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov 2014, 4:80-93.
68. Paraiso K.H.T., et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br. J. Cancer 2010, 102:1724-1730.
69. Solit D.B., et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006, 439:358-362.
70. Wang Y.F., et al. Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res 2007, 13:4934-4942.
71. Wallace E.M., Lyssikatos J.P., Yeh T., Winkler J.D., Koch K. Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy. Curr. Top. Med. Chem 2005, 5:215-229.
72. Adjei A.A., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol 2008, 26:2139-2146.
73. Yeh T.C., et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res 2007, 13:1576-1583.
74. Haass N.K., et al. The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res 2008, 14:230-239.
75. Friday B.B., et al. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer Res 2008, 68:6145-6153.
76. Madhunapantula S.V., Robertson G.P., Is B. Raf a good therapeutic target for melanoma and other malignancies?. Cancer Res 2008, 68:5-8.
77. Kirkwood J.M., et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res 2012, 18:555-567.
78. Robert C., et al. Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncol 2013, 14:733-740.
79. Gilmartin A.G., et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res 2011, 17:989-1000.
80. Falchook G.S., et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012, 13:782-789.
81. Kim K.B., et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol 2013, 31:482-489.
82. Flaherty K.T., et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N. Engl. J. Med 2012, 367:107-114.
83. Hatzivassiliou G., et al. Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers. Nature 2013, 501:232-236.
84. Lito P., et al. Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors. Cancer Cell 2014, 25:697-710.
85. LoRusso P.M., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res 2010, 16:1924-1937.
86. Von Euw E., et al. Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines. Mol. Cancer 2012, 11:22.
87. Zimmer L., et al. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res 2014, 20:4251-4261.
88. King A.J., et al. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions. PLoS ONE 2013, 8:e67583.
89. Flaherty K.T., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N. Engl. J. Med 2012, 367:1694-1703.
90. Long G.V., et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med 2014, 371:1877-1888. 10.1056/NEJMoa1406037.
91. Ribas A., et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. Lancet Oncol 2014, 15:954-965.
92. Gowrishankar K., et al. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. J. Invest. Dermatol 2012, 132:1850-1859.
93. Goldinger S.M., et al. Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. Eur. J. Cancer Oxf. Engl. 1990 2014, 50:406-410.
94. Honda K., et al. Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors. Cancer Chemother. Pharmacol 2013, 72:577-584.
95. Vivanco I., Sawyers C.L. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat. Rev. Cancer 2002, 2:489-501.
96. Davies M.A. The role of the PI3K-AKT pathway in melanoma. Cancer J. Sudbury Mass 2012, 18:142-147.
97. Chudnovsky Y., Adams A.E., Robbins P.B., Lin Q., Khavari P.A. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat. Genet 2005, 37:745-749.
98. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
99. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
100. Luo J., et al. Loss of class IA PI3K signaling in muscle leads to impaired muscle growth, insulin response, and hyperlipidemia. Cell Metab 2006, 3:355-366.
101. Brunet A., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 1999, 96:857-868.
102. Diehl J.A., Cheng M., Roussel M.F., Sherr C.J. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998, 12:3499-3511.
103. Gingras A.C., Kennedy S.G., O'Leary M.A., Sonenberg N., Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev 1998, 12:502-513.
104. Scott P.H., Brunn G.J., Kohn A.D., Roth R.A., Lawrence J.C. Evidence of insulin-stimulated phosphorylation and activation of the mammalian target of rapamycin mediated by a protein kinase B signaling pathway. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:7772-7777.
105. Bellacosa A., et al. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene 1998, 17:313-325.
106. Jacinto E., et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat. Cell Biol 2004, 6:1122-1128.
107. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
108. Hay N., Sonenberg N. Upstream and downstream of mTOR. Genes Dev 2004, 18:1926-1945.
109. Slipicevic A., et al. Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome. Am. J. Clin. Pathol 2005, 124:528-536.
110. Karbowniczek M., Spittle C.S., Morrison T., Wu H., Henske E.P. mTOR is activated in the majority of malignant melanomas. J. Invest. Dermatol 2008, 128:980-987.
111. Dai D.L., Martinka M., Li G. Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol 2005, 23:1473-1482.
112. Restuccia D.F., Hemmings B.A. From man to mouse and back again: advances in defining tumor AKTivities in vivo. Dis. Model. Mech 2010, 3:705-720.
113. Tsao H., Goel V., Wu H., Yang G., Haluska F.G. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol 2004, 122:337-341.
114. Dankort D., et al. Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat. Genet 2009, 41:544-552.
115. Rowinsky E.K. Targeting the molecular target of rapamycin (mTOR). Curr. Opin. Oncol 2004, 16:564-575.
116. Liu P., Cheng H., Roberts T.M., Zhao J.J. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov 2009, 8:627-644.
117. Markman B., Dienstmann R., Tabernero J. Targeting the PI3K/Akt/mTOR pathway-beyond rapalogs. Oncotarget 2010, 1:530-543.
118. Margolin K., et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 2005, 104:1045-1048.
119. Davies M.A., et al. Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res 2012, 18:1120-1128.
120. Margolin K.A., et al. Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438). Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res 2012, 18:1129-1137.
121. Carracedo A., et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest 2008, 118:3065-3074.
122. O'Reilly K.E., et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006, 66:1500-1508.
123. Shi Y., Yan H., Frost P., Gera J., Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol. Cancer Ther 2005, 4:1533-1540.
124. Ogita S., Lorusso P. Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs. Target. Oncol 2011, 6:103-117.
125. Gopal Y.N.V., et al. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res 2010, 70:8736-8747.
126. Maira S.-M., et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther 2008, 7:1851-1863.
127. Marone R., et al. Targeting melanoma with dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors. Mol. Cancer Res. MCR 2009, 7:601-613.
128. Aziz S.A., et al. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res 2010, 16:6029-6039.
129. Greger J.G., et al. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol. Cancer Ther 2012, 11:909-920.
130. Atefi M., et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS ONE 2011, 6:e28973.
131. Paraiso K.H.T., et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res 2011, 71:2750-2760.
132. Cheung M., Sharma A., Madhunapantula S.V., Robertson G.P. Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development. Cancer Res 2008, 68:3429-3439.
133. Jiang C.C., et al. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res 2011, 17:721-730.
134. Roberts P.J., et al. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res 2012, 18:5290-5303.
135. Lassen A., et al. Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma. Mol. Cancer 2014, 13:83.
136. Todd J.R., Scurr L.L., Becker T.M., Kefford R.F., Rizos H. The MAPK pathway functions as a redundant survival signal that reinforces the PI3K cascade in c-Kit mutant melanoma. Oncogene 2014, 33:236-245.
137. Bourillon A., et al. Genetic variation at KIT locus may predispose to melanoma. Pigment Cell Melanoma Res 2013, 26:88-96.
138. Beadling C., et al. KIT gene mutations and copy number in melanoma subtypes. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res 2008, 14:6821-6828.
139. Curtin J.A., Busam K., Pinkel D., Bastian B.C. Somatic activation of KIT in distinct subtypes of melanoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol 2006, 24:4340-4346.
140. Curtin J.A., et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med 2005, 353:2135-2147.
141. Hodi F.S., et al. Major response to imatinib mesylate in KIT-mutated melanoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol 2008, 26:2046-2051.
142. Lutzky J., Bauer J., Bastian B.C. Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. Pigment Cell Melanoma Res 2008, 21:492-493.
143. Brown M.C., Casasola R.J. Complete response in a melanoma patient treated with imatinib. J. Laryngol. Otol 2012, 126:638-640.
144. Jiang X., et al. Imatinib targeting of KIT-mutant oncoprotein in melanoma. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res 2008, 14:7726-7732.
145. Wyman K., et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy. Cancer 2006, 106:2005-2011.
146. Ugurel S., et al. Lack of clinical efficacy of imatinib in metastatic melanoma. Br. J. Cancer 2005, 92:1398-1405.
147. Kim K.B., et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br. J. Cancer 2008, 99:734-740.
148. Carvajal R.D., et al. KIT as a therapeutic target in metastatic melanoma. JAMA J. Am. Med. Assoc 2011, 305:2327-2334.
149. Guo J., et al. Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol 2011, 29:2904-2909.
150. Woodman S.E., et al. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol. Cancer Ther 2009, 8:2079-2085.
151. Kluger H.M., et al. A phase 2 trial of dasatinib in advanced melanoma. Cancer 2011, 117:2202-2208.
152. Cho J.H., Kim K.M., Kwon M., Kim J.H., Lee J. Nilotinib in patients with metastatic melanoma harboring KIT gene aberration. Invest. New Drugs 2012, 30:2008-2014.
153. Afaq F., Adhami V.M., Mukhtar H. Photochemoprevention of ultraviolet B signaling and photocarcinogenesis. Mutat. Res 2005, 571:153-173.
154. Surh Y.-J. Cancer chemoprevention with dietary phytochemicals. Nat. Rev. Cancer 2003, 3:768-780.
155. Syed D.N., et al. Fisetin inhibits human melanoma cell growth through direct binding to p70S6K and mTOR: findings from 3-D melanoma skin equivalents and computational modeling. Biochem. Pharmacol 2014, 89:349-360.
156. Pal H.C., et al. Fisetin inhibits human melanoma cell invasion through promotion of mesenchymal to epithelial transition and by targeting MAPK and NFκB signaling pathways. PLoS ONE 2014, 9:e86338.
157. Syed D.N., et al. Inhibition of human melanoma cell growth by the dietary flavonoid fisetin is associated with disruption of Wnt/β-catenin signaling and decreased Mitf levels. J. Invest. Dermatol 2011, 131:1291-1299.
158. Nihal M., Ahmad N., Mukhtar H., Wood G.S. Anti-proliferative and proapoptotic effects of (-)-epigallocatechin-3-gallate on human melanoma: possible implications for the chemoprevention of melanoma. Int. J. Cancer J. Int. Cancer 2005, 114:513-521.
159. Ellis L.Z., et al. Green tea polyphenol epigallocatechin-3-gallate suppresses melanoma growth by inhibiting inflammasome and IL-1β secretion. Biochem. Biophys. Res. Commun 2011, 414:551-556.
160. Suzuki Y., Isemura M. Inhibitory effect of epigallocatechin gallate on adhesion of murine melanoma cells to laminin. Cancer Lett 2001, 173:15-20.
161. Watanabe T., et al. Higher cell stiffness indicating lower metastatic potential in B16 melanoma cell variants and in (-)-epigallocatechin gallate-treated cells. J. Cancer Res. Clin. Oncol 2012, 138:859-866. 10.1007/s00432-012-1159-5.
162. Singh T., Katiyar S.K. Green tea catechins reduce invasive potential of human melanoma cells by targeting COX-2, PGE2 receptors and epithelial-to-mesenchymal transition. PLoS ONE 2011, 6:e25224.
163. Liu J.D., Chen S.H., Lin C.L., Tsai S.H., Liang Y.C. Inhibition of melanoma growth and metastasis by combination with (-)-epigallocatechin-3-gallate and dacarbazine in mice. J. Cell. Biochem 2001, 83:631-642.
164. Niles R.M., et al. Resveratrol is a potent inducer of apoptosis in human melanoma cells. Cancer Lett 2003, 190:157-163.
165. Wang M., et al. Resveratrol triggers protective autophagy through the ceramide/Akt/mTOR pathway in melanoma B16 cells. Nutr. Cancer 2014, 66:435-440.
166. Gatouillat G., Balasse E., Joseph-Pietras D., Morjani H., Madoulet C. Resveratrol induces cell-cycle disruption and apoptosis in chemoresistant B16 melanoma. J. Cell. Biochem 2010, 110:893-902.
167. Hsieh T., Wang Z., Hamby C.V., Wu J.M. Inhibition of melanoma cell proliferation by resveratrol is correlated with upregulation of quinone reductase 2 and p53. Biochem. Biophys. Res. Commun 2005, 334:223-230.
168. Yang Z., et al. Nitric oxide initiates progression of human melanoma via a feedback loop mediated by apurinic/apyrimidinic endonuclease-1/redox factor-1, which is inhibited by resveratrol. Mol. Cancer Ther 2008, 7:3751-3760.
169. Chen Y.-J., Chen Y.-Y., Lin Y.-F., Hu H.-Y., Liao H.-F. Resveratrol inhibits alpha-melanocyte-stimulating hormone signaling, viability, and invasiveness in melanoma cells. Evid. Based Complement. Altern. Med. ECAM 2013, 2013:632121.
170. Bhattacharya S., Darjatmoko S.R., Polans A.S. Resveratrol modulates the malignant properties of cutaneous melanoma through changes in the activation and attenuation of the antiapoptotic protooncogenic protein Akt/PKB. Melanoma Res 2011, 21:180-187.
171. Trapp V., Parmakhtiar B., Papazian V., Willmott L., Fruehauf J.P. Anti-angiogenic effects of resveratrol mediated by decreased VEGF and increased TSP1 expression in melanoma-endothelial cell co-culture. Angiogenesis 2010, 13:305-315.
172. Cheng Y.-J., et al. Resveratrol enhances chemosensitivity in mouse melanoma model through connexin 43 upregulation. Environ. Toxicol 2014, [Epub ahead of print] PMID:24449132. 10.1002/tox.21952.
173. Yang S., Irani K., Heffron S.E., Jurnak F., Meyskens F.L. Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE/Ref-1) in human melanoma and identification of the therapeutic potential of resveratrol as an APE/Ref-1 inhibitor. Mol. Cancer Ther 2005, 4:1923-1935.
174. Lee M.-H., et al. Direct targeting of MEK1/2 and RSK2 by silybin induces cell-cycle arrest and inhibits melanoma cell growth. Cancer Prev. Res. Phila. Pa 2013, 6:455-465.
175. Vaid M., Prasad R., Sun Q., Katiyar S.K. Silymarin targets β-catenin signaling in blocking migration/invasion of human melanoma cells. PLoS ONE 2011, 6:e23000.
176. Li L.-H., et al. Silymarin enhanced cytotoxic effect of anti-Fas agonistic antibody CH11 on A375-S2 cells. J. Asian Nat. Prod. Res 2007, 9:593-602.
177. Wang L., et al. An anticancer effect of curcumin mediated by down-regulating phosphatase of regenerating liver-3 expression on highly metastatic melanoma cells. Mol. Pharmacol 2009, 76:1238-1245.
178. Bush J.A., Cheung K.J., Li G. Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp. Cell Res 2001, 271:305-314.
179. Dahmke I.N., et al. Curcumin intake affects miRNA signature in murine melanoma with mmu-miR-205-5p most significantly altered. PLoS ONE 2013, 8:e81122.
180. Bakhshi J., et al. Coupling endoplasmic reticulum stress to the cell death program in mouse melanoma cells: effect of curcumin. Apoptosis Int. J. Program. Cell Death 2008, 13:904-914.
181. Marín Y.E., et al. Curcumin downregulates the constitutive activity of NF-kappaB and induces apoptosis in novel mouse melanoma cells. Melanoma Res 2007, 17:274-283.
182. Siwak D.R., Shishodia S., Aggarwal B.B., Kurzrock R. Curcumin-induced antiproliferative and proapoptotic effects in melanoma cells are associated with suppression of IkappaB kinase and nuclear factor kappaB activity and are independent of the B-Raf/mitogen-activated/extracellular signal-regulated protein kinase pathway and the Akt pathway. Cancer 2005, 104:879-890.
183. Zheng M., Ekmekcioglu S., Walch E.T., Tang C.-H., Grimm E.A. Inhibition of nuclear factor-kappaB and nitric oxide by curcumin induces G2/M cell cycle arrest and apoptosis in human melanoma cells. Melanoma Res 2004, 14:165-171.
184. Yu T., Ji J., Guo Y. MST1 activation by curcumin mediates JNK activation, Foxo3a nuclear translocation and apoptosis in melanoma cells. Biochem. Biophys. Res. Commun 2013, 441:53-58.
185. Abusnina A., Keravis T., Yougbaré I., Bronner C., Lugnier C. Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1. Mol. Nutr. Food Res 2011, 55:1677-1689.
186. Hata K., Ishikawa K., Hori K., Konishi T. Differentiation-inducing activity of lupeol, a lupane-type triterpene from Chinese dandelion root (Hokouei-kon), on a mouse melanoma cell line. Biol. Pharm. Bull 2000, 23:962-967.
187. Hata K., et al. Differentiation-inducing activity of lupane triterpenes on a mouse melanoma cell line. Cytotechnology 2006, 52:151-158.
188. Ogiwara K., Hata K. Melanoma cell differentiation induced by lupeol separates into two stages: morphological and functional changes. J. Nat. Med 2009, 63:323-326.
189. Hata K., Hori K., Takahashi S. Role of p38 MAPK in lupeol-induced B16 2F2 mouse melanoma cell differentiation. J. Biochem. (Tokyo) 2003, 134:441-445.
190. Hata K., Hori K., Murata J., Takahashi S. Remodeling of actin cytoskeleton in lupeol-induced B16 2F2 cell differentiation. J. Biochem. (Tokyo) 2005, 138:467-472.
191. Tarapore R.S., et al. Specific targeting of Wnt/β-catenin signaling in human melanoma cells by a dietary triterpene lupeol. Carcinogenesis 2010, 31:1844-1853.
192. Nitta M., et al. Systemic and local injections of lupeol inhibit tumor growth in a melanoma-bearing mouse model. Biomed. Rep 2013, 1:641-645.
193. Saleem M., et al. Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis. Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res 2008, 14:2119-2127.
194. Mannal P.W., Schneider J., Tangada A., McDonald D., McFadden D.W. Honokiol produces anti-neoplastic effects on melanoma cells in vitro. J. Surg. Oncol 2011, 104:260-264.
195. Kaushik G., et al. Honokiol induces cytotoxic and cytostatic effects in malignant melanoma cancer cells. Am. J. Surg 2012, 204:868-873.
196. Martin S., et al. Inducing apoptosis of cancer cells using small-molecule plant compounds that bind to GRP78. Br. J. Cancer 2013, 109:433-443.
197. Moon Y.J., Wang X., Morris M.E. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol. Vitro Int. J. Publ. Assoc. BIBRA 2006, 20:187-210.
198. Khan N., Syed D.N., Ahmad N., Mukhtar H. Fisetin: a dietary antioxidant for health promotion. Antioxid. Redox Signal 2013, 19:151-162.
199. Zheng Y.Y., Viswanathan B., Kesarwani P., Mehrotra S. Dietary agents in cancer prevention: an immunological perspective. Photochem. Photobiol 2012, 88:1083-1098.
200. Soleas G.J., Diamandis E.P., Goldberg D.M. Resveratrol: a molecule whose time has come? And gone?. Clin. Biochem 1997, 30:91-113.
201. Milić N., Milosević N., Suvajdzić L., Zarkov M., Abenavoli L. New therapeutic potentials of milk thistle (Silybum marianum). Nat. Prod. Commun 2013, 8:1801-1810.
202. Yang C.S., Wang X., Lu G., Picinich S.C. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat. Rev. Cancer 2009, 9:429-439.
203. Bill M.A., et al. Curcumin induces proapoptotic effects against human melanoma cells and modulates the cellular response to immunotherapeutic cytokines. Mol. Cancer Ther 2009, 8:2726-2735.
204. Chatterjee S.J., Pandey S. Chemo-resistant melanoma sensitized by tamoxifen to low dose curcumin treatment through induction of apoptosis and autophagy. Cancer Biol. Ther 2011, 11:216-228.
205. Saleem M. Lupeol, a novel anti-inflammatory and anti-cancer dietary triterpene. Cancer Lett 2009, 285:109-115.
206. Ponnurangam S., et al. Honokiol in combination with radiation targets notch signaling to inhibit colon cancer stem cells. Mol. Cancer Ther 2012, 11:963-972.
207. Arbiser J.L., Fisher D.E. Fisetin: a natural fist against melanoma?. J. Invest. Dermatol 2011, 131:1187-1189.